An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The goal of this prospective single-arm open-label trial is to learn about efficacy and safety of Bortezomib in treating patients with difficult-to-treat rheumatoid arthritis. The main questions it aims to answer are:
* Is Bortezomib an effective treatment option for patients with difficult-to-treat rheumatoid arthritis?
* Is Bortezomib safe enough in treating patients with difficult-to-treat rheumatoid arthritis?
Participants will:
* Receive Bortezomib 2 mg per week subcutaneously for twelve weeks in total.
* Follow-up at weeks 4, 12, and 24, while biosamples will be collected.